Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Sees Return To Double-Digit Growth In Second Half Of 2000

This article was originally published in The Gray Sheet

Executive Summary

Resumption of Boston Scientific's historic 20%-plus annual sales growth rate will occur the second half of 2000, the company is assuring investors, as key holes in the firm's product pipeline are filled early in the year, including release of advanced coronary stent systems.

You may also be interested in...



Drug/Device Products High On Piper Analyst's List Of Y2K Trends

The clinical efficacy of reducing restenosis by incorporating the anticancer agent paclitaxel with coronary stents is on the cusp of gaining greater clinical backing, Angiotech Pharmaceuticals indicated.

Boston Scientific's Vanguard AAA Graft Effective For High-Risk Patients

Preliminary data from a study of Boston Scientific's Vanguard aortic endograft for treatment of abdominal aortic aneurysms (AAA) show a 97.6% success rate in high-risk patients. The results reinforce a growing consensus among clinicians that the minimally invasive procedure is preferable to standard open surgery for this population.

Drug/Device Products High On Piper Analyst's List Of Y2K Trends

The clinical efficacy of reducing restenosis by incorporating the anticancer agent paclitaxel with coronary stents is on the cusp of gaining greater clinical backing, Angiotech Pharmaceuticals indicated.

Related Content

UsernamePublicRestriction

Register

MT012719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel